SonR: 35% Risk Reduction in Heart Failure Hospitalization
RESPOND-CRT LANDMARK TRIAL REVEALS A REDUCED RISK IN HEART FAILURE HOSPITALIZATION WITH LIVANOVA'S EXCLUSIVE SONR SENSOR-BASED CRT OPTIMIZATION SYSTEM
The RESPOND-CRT trial was designed to investigate the clinical efficacy and safety of device-based optimization using the SonR cardiac contractility sensor in patients with advanced heart failure. The results, announced today by Prof.
The proprietary SonR optimization system allows for cardiac resynchronization therapy to be continuously adapted to the needs of each patient, thus delivering individualized therapy.
In the RESPOND-CRT trial, optimization with SonR was compared to optimization using echocardiography. Even though echo-guided optimization was considered best practice in terms of reducing the number of non-responders to CRT, it has never been widely adopted in routine practice because of the significant resource consumption it requires.
The overall positive response to CRT reached in the group of patients treated with SonR was 75%, a reduction of approximately 16% in non-responders versus the echo group. In addition to a global favorable effect on long-term heart failure hospitalization, optimization with SonR resulted in a significant improvement in clinical response for patients with a history of atrial fibrillation or renal dysfunction.
"In order to deliver the very best CRT treatment to our heart failure patients, there has been a real need for an optimization solution that is both automatic and efficient," said Prof.
"SonR is a great example of LivaNova's commitment to developing innovative medical technology that really matters, and we would like to thank the participating centers and the several independent committees for their great support in this landmark study," said
About the RESPOND-CRT Trial
The RESPOND-CRT study is a prospective, multicenter, randomized, double-blind study designed to evaluate the safety and efficacy of the SonR system. The trial enrolled 1,039 patients at 125 sites in
The RESPOND-CRT trial is an Investigation Device Exemption (IDE) study approved by the
The study met all of its primary safety and efficacy end points.
The SonRtip lead was proven to be safe, with only 1% of patients reporting lead dislodgement and 0.1% of patients reporting lead fracture.
Optimization with SonR was proven to be as effective as echo-guided optimization based on responder rates. Patients were defined as responders at 12 months based on a hierarchical set of criteria as follows: alive, free from heart failure events, with an improved NYHA functional class or quality of life. Responder rates were 75% in the SonR arm and 70.4% in the Echo arm with the P value [P <0.0001] of the non-inferiority test showing that SonR is as effective as AV and VV echo-guided CRT optimization.
The design of the trial has been published in the
About SonR contractility sensor
The SonR sensor uses measurements of cardiac contractility in order to optimize cardiac resynchronization therapy. The SonR cardiac contractility sensor consists of a micro accelerometer embedded in the tip of the SonRtip atrial lead. The sensor continuously measures the vibrations generated by the myocardium during cardiac contractions which are correlated to cardiac contractility. 3,4,5
The SonRtip lead is connected to a LivaNova CRT-D device featuring an algorithm which automatically adapts the atrioventricular (AV) and interventricular (VV) intervals based on cardiac contractility measurements. Optimization is performed on a weekly basis both at rest and during exercise. This allows for cardiac resynchronization therapy to be continuously adapted to the individual needs of each patient.
SonR technology is available exclusively in LivaNova CRT-D devices including the Paradym, Intensia and Platinium families. The new Platinium CRT-D SonR device was launched in
References
- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. Heart disease and stroke statistics—2013 update: a report from the
American Heart Association . Circulation. 2013;127:e6–e245 - Brugada J, Brachmann J, Delnoy PP, et al. Automatic optimization of cardiac resynchronization therapy using SonR-rationale and design of the clinical trial of the SonRtip lead and automatic AV-VV optimization algorithm in the paradym RF SonR CRT-D (RESPOND-CRT) trial. Am Heart J 2014;167:429-36.
- Rickards AF, Bombardini T, Corbucci G et al. An implantable intracardiac accelerometer for monitoring myocardial contractility. The multicenter PEA Study group. Pacing Clin Electrophysiol 1996;19:2066-2071
- Bongiorni MG, Soldati E, Arena G et al. Local myocardial contractility related to endocardial acceleration signals detected by a transvenous pacing lead. Pacing Clin Electrophysiol 1996;19:1682-1688
- Bordachar P, Garrigue S, Ritter P et al. Contributions of a hemodynamic sensor embedded in an atrial lead in a porcine model. J Cardiovasc Elrctrophysiol. 2011;22(5):579-83
About
Safe harbor statement
This press release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe the Company's future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," "could," "seek," "guidance," "predict," "potential," "likely," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this press release are based on information presently available to
All information in this press release is as of the date of its release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release.
For more information, please visit www.livanova.com, or contact: Investor Relations and Media:Karen King Vice President, Investor Relations & Corporate Communications Phone: +1 (281) 228-7262 Fax: +1 (281) 218-9332 e-mail: corporate.communications@livanova.com